Celgene Corporation (CELG) stock had a bullish inflow of $67.57 million worth of trades on uptick and an outflow of $65.26 million in downticks on Friday. The total uptick to downtick ratio stood at 1.04. The net money flow into the stock was $2.3 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $4.51 million. $4.51 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Celgene Corporation (CELG) stock traded down $0.88 , and reached $105.49, a drop of -0.83% over the previous day. On a weekly basis, the stock is -3.03%, over the previous weeks close.
The company Insiders own 0.97% of Celgene Corporation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -14.62% . Institutional Investors own 78% of Celgene Corporation shares. During last six month period, the net percent change held by insiders has seen a change of -14.85%.
In a related news, The director, of Celgene Corp /De/, Loughlin James J had unloaded 27,500 shares at $114.1 per share in a transaction on August 23, 2016. The total value of transaction was $3,137,750. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Celgene Corporation (NASDAQ:CELG): stock was range-bound between the intraday low of $105.26 and the intraday high of $107 after having opened at $107 on Fridays session. The stock finally closed in the red at $107, a loss of -0.83%. The stock remained in the red for the whole trading day. The total traded volume was 3,274,753 shares. The stock failed to cross $107 in Fridays trading. The stocks closing price on Thursday was $106.37.
Celgene Corporation (CELG) : During the past 4 weeks, traders have been relatively bearish on Celgene Corporation (CELG), hence the stock is down -8.57% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.52% relative to the S&P 500. The 4-week change in the price of the stock is -8.69% and the stock has fallen -3.03% in the past 1 week.
Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.